Online citations, reference lists, and bibliographies.
← Back to Search

In Vitro And In Vivo Evaluation Of An Oral Multiple-unit Formulation For Colonic Delivery Of Insulin.

A. Maroni, M. D. Del Curto, S. Salmaso, L. Zema, A. Melocchi, P. Caliceti, A. Gazzaniga
Published 2016 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
A multiple-unit formulation for time-dependent colonic release of insulin was obtained by coating insulin and sodium glycocholate immediate-release minitablets with: (i) Methocel® E50, a low-viscosity hydroxypropyl methylcellulose (inner coating), (ii) 5:1 w/w Eudragit® NE/Explotab® V17, a mixture of a neutral polymethacrylate with a pore-forming superdisintegrant (intermediate coating), and (iii) Aqoat® AS, enteric-soluble hydroxypropyl methylcellulose acetate succinate (outer coating). Sodium glycocholate was added as a permeation enhancer while the inner, intermediate and outer coatings were aimed, respectively, at delaying the onset of release through swelling/erosion processes, extending the duration of the lag phase by slowing down water penetration into the underlying functional layer, and overcoming variable gastric residence time. In vitro studies showed that neither insulin nor sodium glycocholate were released from the three-layer system during 2h of testing in 0.1N HCl, while complete release of the protein and of the enhancer occurred in phosphate buffer, pH 6.8, after consistent lag phases. No significant changes were noticed in the release profiles following twelve-month storage at 4°C. Oral administration of the novel formulation to diabetic rats elicited a peak in the plasma insulin concentration after 6h, which was associated with a sharp decrease in the glycemic levels. The relative bioavailability and pharmacological availability of such a formulation, as determined vs. the uncoated tablets, were 2.2 and 10.3, respectively. Based on these results, the three-layer system presented was considered a potentially interesting tool for oral colonic delivery of insulin and adjuvant compounds.
This paper references
10.1002/jps.22560
Oral delivery system for two-pulse colonic release of protein drugs and protease inhibitor/absorption enhancer compounds.
M. D. Del Curto (2011)
10.1023/A:1018968611962
Effects of Various Protease Inhibitors on the Intestinal Absorption and Degradation of Insulin in Rats
A. Yamamoto (2004)
10.1023/A:1016213405081
Mucoadhesive Polymers in Peroral Peptide Drug Delivery. II. Carbomer and Polycarbophil Are Potent Inhibitors of the Intestinal Proteolytic Enzyme Trypsin
H. L. Luessen (2004)
10.1016/S0168-3659(96)01582-9
The rationale for peptide drug delivery to the colon and the potential of polymeric carriers as effective tools
A. Rubinstein (1997)
10.1016/S0168-3659(01)00232-2
Development and characterization of a novel peroral peptide drug delivery system.
F. Dorkoosh (2001)
10.1016/J.IJPHARM.2005.09.028
Effects of absorption promoters on insulin absorption through colon-targeted delivery.
M. Katsuma (2006)
10.1016/j.ijpharm.2012.05.075
Polymeric coatings for a multiple-unit pulsatile delivery system: preliminary study on free and applied films.
A. Maroni (2013)
10.1002/JPS.20802
Different HPMC viscosity grades as coating agents for an oral time and/or site-controlled delivery system: an investigation into the mechanisms governing drug release.
L. Zema (2007)
10.1016/0378-5173(81)90010-7
Mechanisms for the enhancement of the nasal absorption of insulin by surfactants
Hirai Shinichiro (1981)
10.1211/0022357991776976
Enhanced Permeability of Insulin across the Rat Intestinal Membrane by Various Absorption Enhancers: Their Intestinal Mucosal Toxicity and Absorption‐enhancing Mechanism of n‐Lauryl‐β‐D‐maltopyranoside
T. Uchiyama (1999)
10.1016/0928-0987(95)00042-9
MUCOADHESIVE POLYMERS IN PERORAL PEPTIDE DRUG DELIVERY. I. INFLUENCE OF MUCOADHESIVE EXCIPIENTS ON THE PROTEOLYTIC ACTIVITY OF INTESTINAL ENZYMES
H. L. Luessen (1996)
10.1016/j.ejpb.2008.12.002
Feasibility, stability and release performance of a time-dependent insulin delivery system intended for oral colon release.
A. Maroni (2009)
Impact of physiological
S. Hurst (1000)
10.1016/j.ijpharm.2009.06.014
Biopharmaceutical characterisation of insulin and recombinant human growth hormone loaded lipid submicron particles produced by supercritical gas micro-atomisation.
S. Salmaso (2009)
10.1016/S0378-5173(98)00400-1
Gastrointestinal transit of pellets in rats: effect of size and density.
C. Tuleu (1999)
10.1016/0168-3659(85)90030-6
The design and evaluation of controlled release systems for the gastrointestinal tract
S. S. Davis (1985)
10.1016/j.addr.2011.10.006
Oral colon delivery of insulin with the aid of functional adjuvants.
A. Maroni (2012)
Feasibility
A. Maroni (2009)
10.1016/J.JDDST.2014.12.003
Coated pellets for oral colon delivery
L. Palugan (2015)
10.1016/j.ijpharm.2013.03.010
Film coatings for oral pulsatile release.
A. Maroni (2013)
10.1002/jps.24150
Erodible time-dependent colon delivery systems with improved efficiency in delaying the onset of drug release.
M. D. Del Curto (2014)
10.1016/0024-3205(90)90492-A
Insulin and proinsulin proteolysis in mucosal homogenates of the albino rabbit: implications in peptide delivery from nonoral routes.
A. Yamamoto (1990)
10.1615/CRITREVTHERDRUGCARRIERSYST.V19.I6.10
The colon as a possible target for orally administered peptide and protein drugs.
S. Haupt (2002)
10.1002/jps.21761
Preparation and evaluation of an oral delivery system for time-dependent colon release of insulin and selected protease inhibitor and absorption enhancer compounds.
M. D. Del Curto (2009)
10.1517/17425225.3.4.469
Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans.
Susan I Hurst (2007)
10.1021/JS970018G
Chitosan Capsules for Colon-Specific Drug Delivery: Improvement of Insulin Absorption from the Rat Colon
H. Tozaki (1997)
10.1517/17425247.3.5.583
Time-controlled oral delivery systems for colon targeting
A. Gazzaniga (2006)
10.1248/BPB.18.891
Susceptibility of insulin to proteolysis in rat lung homogenate and its protection from proteolysis by various protease inhibitors.
Y. Fukuda (1995)
10.2165/00137696-200503030-00003
Polymer colon drug delivery systems and their application to peptides, proteins, and nucleic acids
S. Bourgeois (2005)
Time-dependent oral delivery systems for colon targeting
A. Gazzaniga (1995)
10.1136/gut.27.8.886
Transit of pharmaceutical dosage forms through the small intestine.
S. Davis (1986)
10.1016/S0168-3659(01)00291-7
In vitro and in vivo evaluation of an oral system for time and/or site-specific drug delivery.
M. E. Sangalli (2001)
10.1016/J.JDDST.2015.10.001
Erodible drug delivery systems for time-controlled release into the gastrointestinal tract
A. Maroni (2016)
10.1016/j.ijpharm.2013.05.043
Film coatings for oral colon delivery.
A. Maroni (2013)



This paper is referenced by
10.1016/j.ijpharm.2019.118723
In Vitro and Human Pharmacoscintigraphic Evaluation of an Oral 5-ASA Delivery System for Colonic Release.
A. Foppoli (2019)
10.3390/ijms21061917
Injection Molded Capsules for Colon Delivery Combining Time-Controlled and Enzyme-Triggered Approaches
F. Casati (2020)
10.1038/s41551-020-0559-0
Evolving peptides for oral intake
D. Brayden (2020)
10.1016/j.xphs.2020.02.013
Lego-inspired capsular devices for the development of personalized dietary supplements: proof of concept with multimodal release of caffeine.
A. Melocchi (2020)
10.3390/polym11030517
Effect of Polyethylene Glycol Content and Molar Mass on Injection Molding of Hydroxypropyl Methylcellulose Acetate Succinate-Based Gastroresistant Capsular Devices for Oral Drug Delivery
F. Briatico-Vangosa (2019)
10.1016/j.jff.2020.103801
Dairy-derived peptides for satiety
A. Kondrashina (2020)
10.1007/s40204-017-0072-z
Formulation, physicochemical characterization and in vitro evaluation of human insulin-loaded microspheres as potential oral carrier
G. R. Agrawal (2017)
10.1016/j.apsb.2019.01.004
Multifunctional oral delivery systems for enhanced bioavailability of therapeutic peptides/proteins
Ying Han (2019)
10.1016/j.jconrel.2017.09.025
Animal models for evaluation of oral delivery of biopharmaceuticals
Stine Harloff-Helleberg (2017)
10.1016/j.ejpb.2017.11.012
Retrograded starch/pectin coated gellan gum‐microparticles for oral administration of insulin: A technological platform for protection against enzymatic degradation and improvement of intestinal permeability
A. B. Meneguin (2018)
10.1016/j.ijpharm.2020.119155
3D printing by fused deposition modeling of single- and multi-compartment hollow systems for oral delivery - A review.
A. Melocchi (2020)
10.1080/17425247.2017.1360864
Enteric coatings for colonic drug delivery: state of the art
A. Maroni (2017)
10.1016/j.ejpb.2018.07.008
Preclinical models for colonic absorption, application to controlled release formulation development
Isabel Lozoya‐Agullo (2018)
10.1080/03639045.2020.1788060
Evaluation of powder-layering vs. spray-coating techniques in the manufacturing of a swellable/erodible pulsatile delivery system
A. Foppoli (2020)
Semantic Scholar Logo Some data provided by SemanticScholar